Major League Baseball and their Players Association said they have completed revisions to their Joint Drug Prevention and Treatment Program to include changes made because of the the Ryan Braun arbitration decision, according to a press release.
Some of the changes include: Adding hGH blood testing during Spring Training, during the off-season and studying to expand hGH testing to the regular season. The two sides also will increase the number of random tests during the season and off-season.
The program also added over 45 performance-enhancing substances and stimulants to the list of prohibited substances. “These latest changes and revisions to the Joint Drug Agreement reflect the players’ desire to have the strongest possible Drug Prevention and Treatment Program in professional team sports,” said MLBPA Executive Director Michael Weiner said in the release. “Today’s announcement reflects one of the greatest strengths of the Program – its ability to be improved through the collective bargaining process.”